Pedro P. López‐Casas

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

Rafael Álvarez, Mónica Musteanu, Elena García-García et al. · British Journal of Cancer · 2013 · 291 citations · Full text

Medicine, Oncology, Surgery +17

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma

Beatriz Salvador-Barberó, Mónica Álvarez‐Fernández, Elisabet Zapatero‐Solana et al. · Cancer Cell · 2020 · 180 citations · Full text

Medicine, Oncology, Pharmacology +17

Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Elena Garralda, Keren Paz, Pedro P. López‐Casas et al. · Clinical Cancer Research · 2014 · 149 citations

Medicine, Molecular Genetics, Oncology +16

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Lars D. Engstrom, Ruth Aranda, Matthew Lee et al. · Clinical Cancer Research · 2017 · 147 citations · Full text

Medicine, Oncology, Pharmacology +14

SPARC Expression Did Not Predict Efficacy of <i>nab</i> -Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

Manuel Hidalgo, Carlos Plaza, Mónica Musteanu et al. · Clinical Cancer Research · 2015 · 131 citations · Full text

Medicine, Oncology, Pharmacology +12